Renata ships rivaroxaban capsules to Australia
Renata PLC has shipped its rivaroxaban capsules to Australia, marking the first time the widely used anticoagulant is available in capsule form in the country.
The milestone reflects the company's commitment to pharmaceutical innovation and expanding treatment options for patients.
Rivaroxaban is a key therapy for preventing stroke and systemic embolism, as well as for treating and preventing deep vein thrombosis and pulmonary embolism.
Keep updated, follow The Business Standard's Google news channel
Previously available only as tablets, Renata's new capsule formulation—produced in 15mg and 20mg strengths—is manufactured at its state-of-the-art, TGA-approved facility.
The launch expands Renata's product portfolio in Australia and underscores its focus on delivering advanced, high-quality therapeutic solutions worldwide.
